ESBC
PSTX

E.S. Barr & Co’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

E.S. Barr & Co’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-76,398
Closed -$270K – 89
2022
Q3 		$270K Hold
76,398
– – 0.02% 81
2022
Q2 		$197K Buy
+76,398
New +$212K 0.02% 88

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

E.S. Barr & Co's PSTX Position: Q4 2022 in Review

E.S. Barr & Co sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2022, closing a stake of 76,398 shares — an estimated $270K sold.

E.S. Barr & Co first reported a position in PSTX in Q2 2022 and held it in 2 quarters. The position peaked at $270K in Q3 2022. 89 funds tracked by Wall St. Rank hold PSTX as of Q4 2022.

  • E.S. Barr & Co reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • E.S. Barr & Co sold 76,398 Poseida Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $270K.
  • E.S. Barr & Co first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • E.S. Barr & Co's Poseida Therapeutics, Inc. Common Stock position peaked at $270K in Q3 2022.
  • 89 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2022.

Based on E.S. Barr & Co's 13F filing for Q4 2022, filed 14 Feb 2023.